6467 — TAHO Pharmaceuticals Share Price
Last trade - 00:00- TWD10.61bn
- TWD10.32bn
- TWD8.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 30.77 | ||
| Price to Tang. Book | 30.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5,357.27 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.73% | ||
| Return on Equity | -60.29% | ||
| Operating Margin | -12244.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 6.89 | 6.36 | 1.07 | n/a | 8.41 | n/a | n/a | -7.47% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Taho Pharmaceuticals Ltd a Taiwan-based company that mainly develops Transepithelial Delivery System (TDS) drug delivery technology. The Company absorbs small molecule drugs through the skin or transmucosal absorption, and the dosage forms include transdermal absorption patches, oral dissolving films and buccal dissolving films. The drugs include five major areas, including drugs for cardiovascular diseases, opium addiction withdrawal and overdose emergency drugs, cancer care, central nervous system drugs, and respiratory diseases. In addition to developing new dosage forms of drugs on its own, the Company also accepts commissions from major pharmaceutical companies or biotech companies to develop new dosage forms of products. New drugs under development include the TAH3311 orodispersible film and TAH3341 orodispersible film, TAH2231 buccal-dispersible film, generic drugs include TAH4411 orodispersible film, TAH9922 oral solution, the TAH2211 sublingual orodispersible film and others.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 7th, 2010
- Public Since
- December 30th, 2024
- No. of Employees
- 27
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 52,408,615
- Address
- 3F, TAIPEI, 110
- Web
- https://www.tahopharma.com
- Phone
- +886 226598515
- Contact
- Howard S. Lee
- Auditors
- PricewaterhouseCoopers, Taiwan
Similar to 6467
Adimmune
Taiwan Stock Exchange
BORA PHARMACEUTICALS
Taiwan Stock Exchange
BRIM BIOTECHNOLOGY
Taiwan Stock Exchange
CALIWAY BIOPHARMACEUTICALS
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
FAQ
As of Today at 05:38 UTC, shares in TAHO Pharmaceuticals are trading at TWD202.50. This share price information is delayed by 15 minutes.
Shares in TAHO Pharmaceuticals last closed at TWD202.50 and the price had moved by +21.62% over the past 365 days. In terms of relative price strength the TAHO Pharmaceuticals share price has underperformed the FTSE Developed Asia Pacific Index by -9.68% over the past year.
There is no consensus recommendation for this security.
Find out moreTAHO Pharmaceuticals does not currently pay a dividend.
TAHO Pharmaceuticals does not currently pay a dividend.
TAHO Pharmaceuticals does not currently pay a dividend.
To buy shares in TAHO Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD202.50, shares in TAHO Pharmaceuticals had a market capitalisation of TWD10.61bn.
Here are the trading details for TAHO Pharmaceuticals:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6467
Based on an overall assessment of its quality, value and momentum TAHO Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TAHO Pharmaceuticals. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +81.23%.
As of the last closing price of TWD202.50, shares in TAHO Pharmaceuticals were trading +42.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TAHO Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD202.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on TAHO Pharmaceuticals' directors